Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Researchers at Pfizer Release New Data on Vaccines (Development of a subunit vaccine for prevention of Clostridium difficile associated diseases:...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 10:57pm CEST

Researchers at Pfizer Release New Data on Vaccines (Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B)

By a News Reporter-Staff News Editor at Vaccine Weekly -- New research on Immunization - Vaccines is the subject of a report. According to news reporting originating in Pearl River, New York, by NewsRx journalists, research stated, "Inactivation of bacterial toxins for use in human vaccines traditionally is achieved by treatment with formaldehyde. In contrast, the bivalent experimental vaccine for the prevention of infections (CDI) that is currently being evaluated in clinical trials was produced using a different strategy. toxins A and B were inactivated using site-directed mutagenesis and treatment with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride/-hydroxysulfosuccinimide (EDC/NHS)."

The news reporters obtained a quote from the research from Pfizer, "In the present work we investigate the effect of genetic and chemical modifications on the structure of inactivated toxins (toxoids) A and B. The far-UV circular dichroism (CD) spectra of wild type toxins, mutated toxins, and EDC/NHS-inactivated toxoids reveal that the secondary structure of all proteins is very similar. The near-UV CD spectra show that aromatic residues of all proteins are in a unique asymmetric environment, indicative of well-defined tertiary structure. These results along with the fluorescence emission maxima of 335?nm observed for all proteins suggest that the tertiary structure of toxoids A and B is preserved as well. Analytical ultracentrifugation data demonstrate that all proteins are predominantly monomeric with small fractions of higher molecular weight oligomeric species present in toxoids A and B. Differential scanning calorimetry data reveal that genetic mutations induce thermal destabilization of protein structures. Subsequent treatment with EDC/NHS results either in a minimal (1??C) increase of apparent thermostability (toxoid B) or no change at all (toxoid A)."

According to the news reporters, the research concluded: "Therefore, our two-step inactivation strategy is an effective approach for the preparation of non-toxic proteins maintaining native-like structure and conformation."

For more information on this research see: Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B. Biochemistry and Biophysics Reports, 2017;9():193-202 (see also Immunization - Vaccines).

Our news correspondents report that additional information may be obtained by contacting A. Gribenko, Pfizer Vaccine Research and Development, 401 N Middletown Road, Pearl River, NY 10965, United States. Additional authors for this research include E. Severina, M.K. Sidhu, K.U. Jansen, B.A. Green and Y.V Matsuka.

The direct object identifier (DOI) for that additional information is: http://dx.doi.org/10.1016/j.bbrep.2016.12.015. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: New York, Genetics, Vaccines, Pearl River, Immunization, United States, Biological Products, Risk and Prevention, Clostridium difficile, Gram Positive Bacteria, North and Central America, Gram Positive Endospore Forming Rods, Gram Positive Endospore Forming Bacteria.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
05:19pASTELLAS PHARMA : U.S. FDA Approves XTANDI for the Treatment of Men with Non-Met..
12:45pSEN. BALDWIN TO PFIZER CEO : Make Drug Price Reductions Permanent
12:42pPFIZER : Biotech Stocks Continue Uptrend
10:24aPFIZER : Agrees to Roll Back Price Hikes
09:15aPFIZER : ACRES Unveils Global Quality Standard for Clinical Research Site Accred..
07/16PFIZER : Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene..
07/16PFIZER : to train KSU pharmacy students
07/16PFIZER : Sen. Baldwin, Tammy - (D - WI) News Release
07/14PFIZER : U.S. FDA Approves XTANDI (enzalutamide) for the Treatment of Men With N..
07/13PFIZER : U.S. Patents Awarded to Inventors in New Jersey (July 13)
More news
News from SeekingAlpha
02:16pGilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug 
07/163 THINGS IN BIOTECH, JULY 16 : Array Gets An Important Update 
07/16DIVIDEND SENSEI'S PORTFOLIO UPDATE 4 : The 3 Essential Things All Investors Need.. 
07/16Aquestive Therapeutics Readies $60 Million IPO 
07/16Pfizer launches late-stage study of hemophilia B gene therapy 
Financials ($)
Sales 2018 54 353 M
EBIT 2018 20 784 M
Net income 2018 13 098 M
Debt 2018 21 973 M
Yield 2018 3,65%
P/E ratio 2018 17,20
P/E ratio 2019 15,60
EV / Sales 2018 4,44x
EV / Sales 2019 4,24x
Capitalization 220 B
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,8 $
Spread / Average Target 6,5%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER3.62%219 534
JOHNSON & JOHNSON-9.87%337 763
NOVARTIS-4.54%201 464
ROCHE HOLDING LTD.-5.78%201 132
MERCK AND COMPANY11.23%169 193
AMGEN12.66%129 635